Alkermes/Cephalon Plan Vivitrol Launch In Q2 Following "Approvable" Letter
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Alkermes and Cephalon are preparing a second quarter launch of Vivitrol, a once-monthly naltrexone injection for the treatment of alcohol dependence, after receiving an "approvable" letter from FDA.